Huang Jie J - OmicsDI

Show results for

Unknown (137)
Proteomics (46)
Transcriptomics (14)
Genomics (10)
Metabolomics (6)

Organisms

Homo sapiens (38)
Mus musculus (23)
Cyprinus carpio haematopterus (1)
Escherichia coli (1)
Human CSF-associated densovirus (1)
Mus (1)
Mus sp. (1)
Rattus rattus (1)
Saccharomyces cerevisiae (1)
Sus scrofa (1)
Arabidopsis thaliana (1)

Repository

iProX (40)
biostudies-arrayexpress (16)
EGA (8)
MetaboLights (6)
pride (6)

Tissue

Cell culture (3)
Blood vessel endothelium (1)
Embryonic stem cell (1)
Epithelial cell (1)
Lung (1)
Permanent cell line cell (1)
Plant cell (1)
Seedling (1)

Disease

Cardiovascular system disease (1)
Skin cancer (1)
Wounds and Injuries (1)

Technology Type

Mass Spectrometry (6)
Mass spectrometry (5)
Data-dependent acquisition (2)
Shotgun proteomics (2)
Illumina Genome Analyzer II, Illumina HiSeq 2000 (1)
Mass spectrometry assay (1)
Affinity proteomics (1)
Bottom-up proteomics (1)

Instrument Platform

Liquid Chromatography MS - positive - hilic (2)
Illumina HiSeq 2000 (1)
Liquid Chromatography MS - (1)
Liquid Chromatography MS - Negative (LC-MS (Negative)) (1)
Liquid Chromatography MS - Positive (LC-MS (Positive)) (1)
Liquid Chromatography MS - negative (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)
Xevo G2 QTOF (Waters) (1)

Publication Date

2013 (11)
2022 (10)
2024 (8)
2025 (7)
2023 (5)
2012 (3)
2017 (2)
2026 (2)
2014 (1)
2018 (1)
2021 (1)

CHEBI ID

CHEBI:15765 (3)
CHEBI:15891 (3)
CHEBI:16610 (3)
CHEBI:27266 (3)
CHEBI:27897 (3)
CHEBI:28931 (3)
CHEBI:37024 (3)
CHEBI:101085 (2)
CHEBI:116314 (2)
CHEBI:133919 (2)
CHEBI:134676 (2)
CHEBI:138857 (2)
CHEBI:142245 (2)
CHEBI:15354 (2)
CHEBI:15634 (2)
CHEBI:15694 (2)
CHEBI:15728 (2)
CHEBI:15746 (2)
CHEBI:15772 (2)
CHEBI:15830 (2)
CHEBI:15882 (2)
CHEBI:15947 (2)
CHEBI:15956 (2)
CHEBI:15999 (2)
CHEBI:16040 (2)
CHEBI:16235 (2)
CHEBI:16257 (2)
CHEBI:16279 (2)
CHEBI:16286 (2)
CHEBI:16347 (2)

Metabolite Name

Aminoadipic acid (2)
Choline (2)
Creatine (2)
Cytosine (2)
Indole-3-acetaldehyde (2)
Methionine (2)
Proline (2)
Putrescine (2)
Spermidine (2)
Thiodiacetic acid (2)
Valine (2)
(+)-12-(2-Cyclopenten-1-yl)-2-dodecanone (1)
(+)-8'-hydroxyabscisic acid (1)
(+)-Catechin (1)
(+)-Demethoxyaschantin (1)
(+)-Syringaresinol O-beta-D-glucoside (1)
(+)-gamma-Hydroxy-L-homoarginine (1)
(+/-)-6-Acetonyldihydrochelerythrine (1)
(+/-)-6-Acetonyldihydrosanguinarine (1)
(-)-11-hydroxy-9,10-dihydrojasmonic acid 11-beta-d-glucoside (1)
(-)-Acanthocarpan (1)
(-)-Apparicine (1)
(-)-Deltoin (1)
(-)-Epigallocatechin (1)
(-)-Glyceollin II (1)
(-)-Medicocarpin (1)
(-)-Solanapyrone A (1)
(-)-lupinine (1)
(1-Ribosylimidazole)-4-acetate (1)
(10S)-Juvenile hormone III acid diol (1)

Study type

Transcription profiling by array (8)
RNA-seq of coding RNA (5)
ChIP-seq (2)
Comparative genomic hybridization by array (1)

Release Date

2025 (28)
2021 (17)
2013 (14)
2020 (14)
2022 (13)
2024 (12)
2017 (9)
2023 (9)
2019 (9)
2018 (7)
2026 (6)
2015 (6)
2016 (4)
2012 (3)
2014 (1)
2007 (1)

Lab affiliation

Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, China (1)
Immunogenetics Laboratory, Shenzhen Blood Center, Shenzhen 518040, China (1)
Shenzhen Key Laboratory of Plant Genetic Engineering and Molecular Design, Institute of Plant and Food Science, Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China (1)
The First Affiliated Hospital, School of Medicine, Zhejiang University (1)
The second affiliated Hospital, Guangzhou Medical University (1)
shandong normal university (1)

Previous page
1 / 22
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 22
Next page

Sort by:

Relevance

Page size

¹H NMR-Based Metabolomics Reveals Refined-Huang-Lian-Jie-Du-Decoction (BBG) as a Potential Ischemic Stroke Treatment Drug With Efficacy and a Favorable Therapeutic Window.

Huang-Lian-Jie-Du-Decoction (HLJDD) is a traditional Chinese medicine (TCM) used to treat ischemic stroke. However, the complexity of its chemical composition makes quality control difficult. Berberine, baicalin, and geniposide are the three main ingredients in HLJDD. Here, a formula of BBG comprise...

S-EPMC6474285 | biostudies-literature

Bioinformatics analysis for the antirheumatic effects of huang-lian-jie-du-tang from a network perspective.

Huang-Lian-Jie-Du-Tang (HLJDT) is a classic TCM formula to clear "heat" and "poison" that exhibits antirheumatic activity. Here we investigated the therapeutic mechanisms of HLJDT at protein network level using bioinformatics approach. It was found that HLJDT shares 5 target proteins with 3 types of...

S-EPMC3856148 | biostudies-literature

The components of Huang-Lian-Jie-Du-Decoction act synergistically to exert protective effects in a rat ischemic stroke model.

Huang-Lian-Jie-Du-Decoction (HLJDD, Oren-gedoku-to in Japanese) is commonly used in traditional Chinese medicine (TCM) to treat ischemic stroke. This study investigated the efficacy of various combinations of the major components of HLJDD, berberine (A), baicalin (B), and jasminoidin (C), on the tre...

S-EPMC5348361 | biostudies-literature

Treatment Effects of Ischemic Stroke by Berberine, Baicalin, and Jasminoidin from Huang-Lian-Jie-Du-Decoction (HLJDD) Explored by an Integrated Metabolomics Approach.

Berberine, baicalin, and jasminoidin were major active ingredients of Huang-Lian-Jie-Du-Decoction (HLJDD), a famous prescription of traditional Chinese medicine (TCM), which has been used for the treatment of ischemic stroke. The aim of the present study was to classify their roles in the treatment ...

S-EPMC5574319 | biostudies-literature

Optimization of Huang-Lian-Jie-Du-Decoction for Ischemic Stroke Treatment and Mechanistic Study by Metabolomic Profiling and Network Analysis.

Optimal drug proportions and mechanism deciphering of multicomponent drugs are critical for developing novel therapies to cope with complex diseases, such as stroke. In the present study, orthogonal experimental design was applied to explore the optimal proportion of the four component herbs in Huan...

S-EPMC5368223 | biostudies-literature

Intermodule Coupling Analysis of Huang-Lian-Jie-Du Decoction on Stroke.

Huang-Lian-Jie-Du Decoction (HLJDD) is a "Fangji" made up of well-designed Chinese herb array and widely used to treat ischemic stroke. Here we aimed to investigate pharmacological mechanism by introducing an inter-module analysis to identify an overarching view of target profile and action mode of ...

S-EPMC6848980 | biostudies-literature

Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1.

Huang-Lian-Jie-Du-Tang (HLJDT), a traditional formula with four TCM herbs, has been used for hundred years for different diseases. The current study aimed to assess the inhibitory activity of HLJDT against H1N1 neuraminidase (NA-1), and identify potent NA-1 inhibitors from its plasma profile. The in...

S-EPMC5686190 | biostudies-literature

Modulation of double-negative T cells by Huang-Lian-Jie-Du Decoction attenuates neuroinflammation in ischemic stroke: insights from single-cell transcriptomics.

Introduction

Ischemic stroke (IS) represents a significant global health challenge, characterized by elevated morbidity and mortality rates, largely driven by inflammatory responses. Double-negative T cells (DNTs), a distinct subset of T cells lacking both CD4 and CD8 markers, have been impl...

S-EPMC11865039 | biostudies-literature

Huang-Lian-Jie-Du decoction alleviates cognitive deficits in Alzheimer's disease model 5xFAD mice by inhibiting Trem2/Dap12 signaling pathway.

Background

Alzheimer's disease (AD) is a progressive neurodegenerative disorder predominantly affecting the elderly population. It is characterized by cognitive deficits associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles. Huang-Lian-Jie-Du (HLJD) decoction, ...

S-EPMC11998141 | biostudies-literature

Huang Lian Jie Du Decoction enhances the anti-tumor efficacy of immune checkpoint inhibitors by activating TLR7/8 signalling in melanoma.

Background

The clinical application of immune checkpoint inhibitors (ICIs) is limited by their drug resistance, necessitating the development of ICI sensitizers to improve cancer immunotherapy outcomes. Huang Lian Jie Du Decoction (HLJD, Oren-gedoku-to in Japanese, Hwangryunhaedok-tang in Ko...

S-EPMC11007990 | biostudies-literature

Previous page
1 / 22
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 22
Next page

Sort by:

Relevance

Page size

213 Results

Show results for

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

Study type

Release Date

Lab affiliation

Introduction

Background

Background

OmicsDI is part of the ELIXIR infrastructure

Tweets